Effect of intravenous zoledronic acid (ZA) on bone metastasis in patients with metastatic renal cell cancer (mRCC)

被引：0
|
作者：
Gruenwald, V. [1 ]
Wirth, M. [2 ]
Zantl, N. [3 ]
Schulze, M.
May, C. [4 ]
Ruebel, A. [4 ]
Tunn, U. [5 ]
机构：
[1] Hannover Med Sch, D-30623 Hannover, Germany
[2] Univ Klinikum Carl Gustav Carus Dresden, Dresden, Germany
[3] Klinikum Konstanz, Constance, Germany
[4] Novartis Pharma GmbH, Nurnberg, Germany
[5] Stadt Kliniken Offenbach, Offenbach, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [21] Burden of cancer in metastatic renal cell carcinoma (mRCC).
    Battle, Dena
    Griffith, Meghan
    Msaouel, Pavlos
    Psutka, Sarah P.
    Vaishampayan, Ulka N.
    Zhang, Tian
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [22] Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer
    Saad, Fred
    Eastham, James A.
    SEMINARS IN ONCOLOGY, 2010, 37 (03) : S38 - S44
  • [23] Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
    Aguiar Bujanda, D.
    Bohn Sarmiento, U.
    Cabrera Suarez, M. A.
    Aguiar Morales, J.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 556 - 560
  • [24] The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
    Zarogoulidis, Kostantinos
    Boutsikou, Eufimia
    Zarogoulidis, Pavlos
    Eleftheriadou, Ellada
    Kontakiotis, Theodore
    Lithoxopoulou, Hellie
    Tzanakakis, George
    Kanakis, Ioannis
    Karamanos, Nikos K.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (07) : 1705 - 1709
  • [25] The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
    Hoshi, S.
    Numahata, K.
    Ono, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Late onset of bone metastases is a positive prognostic parameter in metastatic renal cell cancer (mRCC) treated with sunitnib: Experience in 82 mRCC patients
    Ivanyi, P.
    Koenig, J.
    Busch, J.
    Trummer, A.
    Seidel, C.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 90 - 91
  • [27] Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients:: Comparative bone turnover marker and safety data
    Body, JJ
    Lichinitser, M
    Coleman, RE
    Bergström, B
    BONE, 2006, 38 (03) : S69 - S69
  • [28] Safety of zoledronic acid in bone metastatic breast cancer patients:: A retrospective analysis
    Ferraro, Giuseppa
    Caristi, Nicola
    Sacca, Marcello Maugeri
    Arcana, Concetta
    Adamo, Barbara
    Briguglio, Roberta
    Zanghi, Mariangela
    Adamo, Vincenzo
    ANNALS OF ONCOLOGY, 2007, 18 : 46 - 46
  • [29] Renal safety of prolonged i. v. zoledronic acid (ZA) administration in patients with bone metastases
    Turano, S.
    Liguori, V.
    Ceniti, S.
    Biamonte, R.
    DeSimone, R.
    Filice, A.
    Manfredi, C.
    Mastroianni, C.
    Rovito, A.
    Palazzo, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 78 - 78
  • [30] The effect of denosumab on kidney function in patients with metastatic breast cancer to bone previously treated with zoledronic acid
    Purvey, Sneha
    Leventakos, Konstantinos
    Munjoma, Mutsa S.
    Sherman, Michael J.
    Desale, Sameer
    Herbolshelmer, Pla Maarit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345